Literature DB >> 26297056

E-cadherin expression in obesity-associated, Kras-initiated pancreatic ductal adenocarcinoma in mice.

Alexander P Stark1, Hui-Hua Chang1, Xiaoman Jung1, Aune Moro1, Kathleen Hertzer1, Mu Xu1, Andrea Schmidt1, O Joe Hines1, Guido Eibl2.   

Abstract

BACKGROUND: The epithelial-mesenchymal transition (EMT) is critical in the development of invasive epithelial malignancies. EMT is accelerated by inflammation and results in decreased E-cadherin expression. Diet-induced obesity is an inflammatory state that accelerates pancreatic carcinogenesis; its effect on EMT and E-cadherin expression in the development of pancreatic ductal adenocarcinoma is unclear.
METHODS: Conditional Kras(G12D) mice were fed a control diet or a high-fat, high-calorie diet for 3 or 9 months (n = 10 each). Immunohistochemistry with anti-E-cadherin antibody was performed. E-cadherin expression was characterized by staining intensity, location, and proportion of positive cells. In vitro expression of E-cadherin and Slug in primary pancreatic intraepithelial neoplasia (PanIN) and cancer cells was determined by Western blot.
RESULTS: The HFCD led to increased weight gain in both 3- (15.8 vs 5.6 g, P < .001) and 9-month (19.8 vs 12.9 g, P = .007) mice. No differences in E-cadherin expression among various stages of preinvasive PanIN lesions were found--regardless of age or diet. In invasive cancer, E-cadherin expression was aberrant, with loss of membranous staining and prominent cytoplasmic staining, associated with strong, cytoplasmic expression of β-catenin. In vitro expression of E-cadherin was greatest in primary PanIN cells, accompanied by absent Slug expression. Cancer cell lines demonstrated significantly decreased E-cadherin expression in the presence of upregulated Slug.
CONCLUSION: Despite increased pancreatic inflammation and accelerated carcinogenesis, the high-fat, high-calorie diet did not induce changes in E-cadherin expression in PanIN lesions of all stages. Invasive lesions demonstrated aberrant cytoplasmic E-cadherin staining. Loss of normal membranous localization may reflect a functional loss of E-cadherin.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26297056      PMCID: PMC4637247          DOI: 10.1016/j.surg.2015.07.023

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  35 in total

1.  Leptin-induced epithelial-mesenchymal transition in breast cancer cells requires β-catenin activation via Akt/GSK3- and MTA1/Wnt1 protein-dependent pathways.

Authors:  Dan Yan; Dimiter Avtanski; Neeraj K Saxena; Dipali Sharma
Journal:  J Biol Chem       Date:  2012-01-23       Impact factor: 5.157

Review 2.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

3.  Pancreatic cancer: epidemiology and risk factors.

Authors:  Guenter J Krejs
Journal:  Dig Dis       Date:  2010-09-01       Impact factor: 2.404

4.  The epithelial-mesenchymal transition generates cells with properties of stem cells.

Authors:  Sendurai A Mani; Wenjun Guo; Mai-Jing Liao; Elinor Ng Eaton; Ayyakkannu Ayyanan; Alicia Y Zhou; Mary Brooks; Ferenc Reinhard; Cheng Cheng Zhang; Michail Shipitsin; Lauren L Campbell; Kornelia Polyak; Cathrin Brisken; Jing Yang; Robert A Weinberg
Journal:  Cell       Date:  2008-05-16       Impact factor: 41.582

Review 5.  Obesity related hyperinsulinaemia and hyperglycaemia and cancer development.

Authors:  Susen Becker; Laure Dossus; Rudolf Kaaks
Journal:  Arch Physiol Biochem       Date:  2009-05       Impact factor: 4.076

6.  Obesity-related systemic factors promote an invasive phenotype in prostate cancer cells.

Authors:  R S Price; D A Cavazos; R E De Angel; S D Hursting; L A deGraffenried
Journal:  Prostate Cancer Prostatic Dis       Date:  2012-02-14       Impact factor: 5.554

7.  Loss of membrane localization and aberrant nuclear E-cadherin expression correlates with invasion in pancreatic endocrine tumors.

Authors:  Runjan Chetty; Stefano Serra; Sylvia L Asa
Journal:  Am J Surg Pathol       Date:  2008-03       Impact factor: 6.394

8.  Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan).

Authors:  Alan A Arslan; Kathy J Helzlsouer; Charles Kooperberg; Xiao-Ou Shu; Emily Steplowski; H Bas Bueno-de-Mesquita; Charles S Fuchs; Myron D Gross; Eric J Jacobs; Andrea Z Lacroix; Gloria M Petersen; Rachael Z Stolzenberg-Solomon; Wei Zheng; Demetrius Albanes; Laufey Amundadottir; William R Bamlet; Aurelio Barricarte; Sheila A Bingham; Heiner Boeing; Marie-Christine Boutron-Ruault; Julie E Buring; Stephen J Chanock; Sandra Clipp; J Michael Gaziano; Edward L Giovannucci; Susan E Hankinson; Patricia Hartge; Robert N Hoover; David J Hunter; Amy Hutchinson; Kevin B Jacobs; Peter Kraft; Shannon M Lynch; Jonas Manjer; Joann E Manson; Anne McTiernan; Robert R McWilliams; Julie B Mendelsohn; Dominique S Michaud; Domenico Palli; Thomas E Rohan; Nadia Slimani; Gilles Thomas; Anne Tjønneland; Geoffrey S Tobias; Dimitrios Trichopoulos; Jarmo Virtamo; Brian M Wolpin; Kai Yu; Anne Zeleniuch-Jacquotte; Alpa V Patel
Journal:  Arch Intern Med       Date:  2010-05-10

9.  EMT and dissemination precede pancreatic tumor formation.

Authors:  Andrew D Rhim; Emily T Mirek; Nicole M Aiello; Anirban Maitra; Jennifer M Bailey; Florencia McAllister; Maximilian Reichert; Gregory L Beatty; Anil K Rustgi; Robert H Vonderheide; Steven D Leach; Ben Z Stanger
Journal:  Cell       Date:  2012-01-20       Impact factor: 41.582

10.  Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas.

Authors:  Seung-Mo Hong; Ang Li; Kelly Olino; Christopher L Wolfgang; Joseph M Herman; Richard D Schulick; Christine Iacobuzio-Donahue; Ralph H Hruban; Michael Goggins
Journal:  Mod Pathol       Date:  2011-05-06       Impact factor: 7.842

View more
  6 in total

1.  Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.

Authors:  Evan S Glazer; Omar M Rashid; Jose M Pimiento; Pamela J Hodul; Mokenge P Malafa
Journal:  Surgery       Date:  2016-07-20       Impact factor: 3.982

2.  Prognostic Significance of Preoperative Neutrophil-to-Lymphocyte Ratio in Surgically Resectable Pancreatic Neuroendocrine Tumors.

Authors:  Bo Zhou; Canyang Zhan; Jingjing Wu; Jianhua Liu; Jie Zhou; Shusen Zheng
Journal:  Med Sci Monit       Date:  2017-11-23

3.  Extra-pancreatic invasion induces lipolytic and fibrotic changes in the adipose microenvironment, with released fatty acids enhancing the invasiveness of pancreatic cancer cells.

Authors:  Takashi Okumura; Kenoki Ohuchida; Masafumi Sada; Toshiya Abe; Sho Endo; Kazuhiro Koikawa; Chika Iwamoto; Daisuke Miura; Yusuke Mizuuchi; Taiki Moriyama; Kohei Nakata; Yoshihiro Miyasaka; Tatsuya Manabe; Takao Ohtsuka; Eishi Nagai; Kazuhiro Mizumoto; Yoshinao Oda; Makoto Hashizume; Masafumi Nakamura
Journal:  Oncotarget       Date:  2017-03-14

Review 4.  Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance.

Authors:  Priscilla Cascetta; Alessandro Cavaliere; Geny Piro; Lorena Torroni; Raffaela Santoro; Giampaolo Tortora; Davide Melisi; Carmine Carbone
Journal:  Int J Mol Sci       Date:  2018-10-25       Impact factor: 5.923

5.  The expression of genes contributing to pancreatic adenocarcinoma progression is influenced by the respective environment.

Authors:  Micah N Sagini; Michael Zepp; Frank Bergmann; Matthias Bozza; Richard Harbottle; Martin R Berger
Journal:  Genes Cancer       Date:  2018-03

6.  Clinical significance of the preoperative main pancreatic duct dilation and neutrophil-to-lymphocyte ratio in pancreatic neuroendocrine tumors (PNETs) of the head after curative resection.

Authors:  Bo Zhou; Canyang Zhan; Jie Xiang; Yuan Ding; Sheng Yan
Journal:  BMC Endocr Disord       Date:  2019-11-12       Impact factor: 2.763

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.